Use of azithromycin in the treatment of acute exacerbations of COPD

International Journal of COPD

Volumn 3, Issue 4, 2008, Pages 515-520

  Milstone, Aaron P ^a  

^a VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Azithromycin; COPD acute exacerbation; Macrolide

Indexed keywords

AMOXICILLIN; AMOXICILLIN PLUS CLAVULANIC ACID; AZITHROMYCIN; CEFACLOR; CLARITHROMYCIN; DIRITHROMYCIN; LEVOFLOXACIN; MOXIFLOXACIN; PIVAMPICILLIN; ROXITHROMYCIN; TRIPAK; UNCLASSIFIED DRUG; ZPACK;

CHRONIC BRONCHITIS; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL TRIAL; DISEASE EXACERBATION; DOSAGE SCHEDULE COMPARISON; DRUG EFFICACY; FORCED EXPIRATORY VOLUME; GASTROINTESTINAL TOXICITY; HUMAN; REVIEW; SHORT COURSE THERAPY; SINGLE DRUG DOSE;

ANTI-INFECTIVE AGENTS; AZITHROMYCIN; BRONCHITIS, CHRONIC; CHEMISTRY, PHARMACEUTICAL; DRUG ADMINISTRATION SCHEDULE; HUMANS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RECURRENCE; TREATMENT OUTCOME;

EID: 60249099790     PISSN: 11769106     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (52)

1. Amsden GW, Baird IM, Simon S, et al. 2003. Efficacy and safety of azithromycin vs levofloxacin in the outpatient treatment of acute bacterial exacerbations of chronic bronchitis. Chest, 123:772-7.
2. Amsden GW, Nafziger AN, Foulds G. 1999. Pharmacokinetics in serum and leukocyte exposures of oral azithromycin, 1,500 milligrams, given over a 3- or 5-day period in healthy subjects. Antimicrob Agents Chemother, 43:163-5.
3. Amsden GW. 2005. Anti-inflammatory effects of macrolides - an underappreciated benefit in the treatment of community-acquired respiratory tract infections and chronic inflammatory pulmonary conditions? J Antimicrob Chemother, 55:10-21.
4. Anthonisen NR, Manfreda J, Warren CPW, et al. 1987. Antibiotic therapy in exacerbations of chronic obstructive pulmonary disease. Ann Intern Med, 106:196-204.
5. Beghi G, Berni F, Carrutu L, et al. 1995. Efficacy and tolerability of azithromycin versus amoxicillin/clavulanic acid in acute purulent exacerbation of chronic bronchitis. J Chemother, 7:146-52.
6. Biebuyck XA. 1996. Comparison of azithromycin and co-amoxiclav in the treatment of acute tracheobronchitis and acute infectious exacerbations of chronic bronchitis in adults. Azithromycin Study Group. J Int Med Res, 24:407-18.
7. Bradbury F. 1993. Comparison of azithromycin versus clarithromycin in the treatment of patients with lower respiratory tract infection. J Antimicrob Chemother, 31(Suppl E):153-62.
8. Castaldo RS, Celli BR, Gomez F, et al. 2003. A comparison of 5-day courses of dirithromycin and azithromycin in the treatment of acute exacerbations of chronic obstructive pulmonary disease. Clin Ther, 25:542-57.
9. Cazzola M, Salzillo A, De Giglio C, et al. 2005. Treatment of acute exacerbation of severe-to-very severe COPD with azithromycin in patients vaccinated against Streptococcus pneumoniae. Respir Med, 99:663-9.
10. Cazzola M, Vinciguerra A, Di Perna F, et al. 1999. Comparative study of dirithromycin and azithromycin in the treatment of acute bacterial exacerbations of chronic bronchitis. J Chemother, 11:119-25.
11. Clinical trials [online]. http://clinicaltrials.gov/ct/gui/ search?term=azithromycin. Accessed December 2006.
12. Craig WA. 1997. Postantibiotic effects and the dosing of macrolides, azalides, and streptogramins. In Zinner SH, Young LS, Acar JF et al. (eds). Expanding indications for the new macrolides, azalides, and streptogramins New York: Marcel Dekker. pp. 27-38.
13. Cymbala AA, Edmonds LC, Bauer MA, et al. 2005. The disease-modifying effects of twice-weekly oral azithromycin in patients with bronchiectasis. Treat Respir Med, 4:117-22.
14. Dark D. 1993. zithromycin versus cefaclor in the treatment of acute exacerbations of chronic obstructive pulmonary disease. Curr Ther Res, 53:203-11.
15. Davies G, Wilson R. 2004. Prophylactic antibiotic treatment of bronchiectasis with azithromycin. Thorax, 59:540-1.
16. DeAbate CA, Mathew CP, Warner JH, et al. 2000. The safety and efficacy of short course (5-day) moxifloxacin versus azithromycin in the treatment of patients with acute exacerbations of chronic bronchitis. Respir Med, 94:1029-37.
17. Destache CJ, Dewan N, O'Donohue WJ, et al. 1999. Clinical and economic considerations in the treatment of acute exacerbations of chronic bronchitis. J Antimicrob Chemother, 43(Suppl A):107-13.
18. Doern GV, Heilmann KP, Huynh HK, et al. 2001. Antimicrobial resistance among clinical isolates of Streptococcus pneumoniae in the United States during 1999-2000, including a comparison of resistance rates since 1994-1995. Antimicrob Agents Chemother, 45:1721-9.
19. Donaldson G, Seemungal TA, Bhowmik A, et al. 2002. Relationship between exacerbation frequency and lung function decline in chronic obstructive disease. Thorax, 57:847-52.
20. Drug Details. FDA Home Page. 2006 [online]. Accessed: December 2006. Available from: http://www.accessdata.fda.gov/scripts/cder/drugsatfda/ index.cfm?fuseaction=Search.DrugDetails.
21. Equi A, Balfour-Lynn IM, Bush A, et al. 2002. Long term azithromycin in children with cystic fibrosis: a randomised, placebo-controlled crossover trial. Lancet, 360(9338):978-84.
22. Farrell DJ, File TM, Jenkins SG. 2006. Prevalence and antibacterial susceptibility of mef(a)-positive macrolide-resistant Streptococcus pneumoniae over 4 years of the PROTEKT US Study (2000-2004). J Clin Microbiol, 45:290-3.
23. Foulds G, Shepard RM, Johnson RB. 1990. The pharmacokinetics of azithromycin in human serum and tissues. J Antimicrob Chemother, 25(Suppl A):73-82.
24. Gomez J, Banos V, Simarro E, et al. 2000. Prospective, comparative study (1994-1998) of the influence of short-term prophylactic treatment with azithromycin on patients with advanced COPD. Rev Esp Quimioter, 133:79-83.
25. Gris P. 1996. Once-daily, 3-day azithromycin versus a three-times-daily, 10-day course of co-amoxiclav in the treatment of adults with lower respiratory tract infections: results of a randomized, double-blind comparative study. J Antimicrob Chemother, 37(Suppl C):93-101.
26. Grossman R, Mukherjee J, Vaughan D, et al. 1998. A 1-year community-based health economic study of ciprofloxacin vs usual antibiotic treatment in acute exacerbations of chronic bronchitis: the Canadian Ciprofloxacin Health Economic Study Group. Chest, 113:131-41.
27. Hoepelman IM, Mollers MJ, van Schie MH, et al. 1997. A short (3-day) course of azithromycin tablets versus a 10-day course of amoxycillin-clavulanic acid (co-amoxiclav) in the treatment of adults with lower respiratory tract infections and effects on long-term outcome. Int J Antimicrob Agents, 9:141-6.
28. Jacobs MR. 2003. Worldwide trends in antimicrobial resistance among common respiratory tract pathogens in children. Pediatr Infect Dis J, 22:S109-S19.
29. Kanner R, Anthonisen N, Connett J. 2001. Ower respiratory illnesses promote FEV1 decline in current smokers but not ex-smokers with mild chronic obstructive pulmonary disease. Am J Respir Crit Care Med, 164:358-64.
30. Koch CC, Esteban DJ, Chin AC, et al. 2000. Apoptosis, oxidative metabolism and interleukin-8 production in human neutrophils exposed to azithromycin: effects of Streptococcus pneumoniae. J Antimicrob Chemother, 46:19-26.
31. Kreis SR, Herrera N, Golzar N, et al. 2000. for the Therapeutic Circles Bronchitis Study Group. A comparison of moxifloxacin and azithromycin in the treatment of acute exacerbations of chronic bronchitis. JCOM, 7:33-37.
32. Lantero M, Portillo A, Gastañarea MJ, et al. 1998. MLS resistance phenotypes and mechanisms in S. pneumoniae. In Program and Abstracts of the Fourth International Conference on the Macrolides, Azalides, Streptogramins and Ketolides, Barcelona, Spain, 1998. Abstract 3.10, Wallace Communications, Inc., Atlanta, GA.
33. Laurent K. 1996. Efficacy, safety and tolerability of azithromycin versus roxithromycin in the treatment of acute lower respiratory tract infections. J Antimicrob Chemother, 37(Suppl C):115-24.
34. Liu P, Allaudeen H, Chandra R, et al. 2007. Comparative pharmacokinetics of azithromycin in serum and white blood cells of healthy subjects receiving a single-dose extended-release regimen versus a 3-day immediate release regimen. Antimicrob Agents Chemother, 51:110-8.
35. Low DE, de Azavedo J, Weiss K, et al. 2002. Antimicrobial resistance among clinical isolates of Streptococcus pneumoniae in Canada during 2000. Antimicrob Agents Chemother, 46:1295-301.
36. Low DE. 2004. Resistance trends in Haemophilus influenzae (PROTEKT years 1-3 (1999-2002). J Chemother, 16(Suppl 6):49-61.
37. Mertens JC, van Barneveld PW, Asin HR, et al. 1992. Double-blind randomized study comparing the efficacies and safeties of a short (3-day) course of azithromycin and a 5-day course of amoxicillin in patients with acute exacerbations of chronic bronchitis. Antimicrob Agents Chemother, 36:1456-9.
38. Milstone A, Patsimas J, Farzan D; the PROPeR Use Study Group. 2005. Prospective observational study of patient-reported outcomes for azithromycin versus usual care in the treatment of bacterial acute exacerbation of chronic bronchitis. Clin Ther, 27:926-39.
39. Powis J, McGeer A, Green K, et al. 2004. In vitro antimicrobial susceptibilities of Streptococcus pneumoniae clinical isolates obtained in Canada in 2002. Antimicrob Agents Chemother, 48:3305-11.
40. Saiman L, Marshall BC, Mayer-Hamblett N, et al. 2003. Azithromycin in patients with cystic fibrosis chronically infected with Pseudomonas aeruginosa: a randomized controlled trial. JAMA, 290:1749-56.
41. Saint S., Bent S, Vittinghoff E. 1995. Antibiotics in chronic obstructive pulmonary disease: a meta-analysis. J Am Med Assoc, 273:957-60.
42. Schouenborg P, Gerdes N, Rasmussen H, et al. 2000. Azithromycin versus pivampicillin in the treatment of acute exacerbations of chronic bronchitis: a single-blind, double-dummy, multicentre study. J Int Med Res, 28:101-10.
43. Snow V, Lascher S, Mottus-Pilson C. 2001. for the Joint Expert Panel on COPD of the American College of Chest Physicians and the American College of Physicians-American Society of Internal Medicine. The evidence base for management of acute exacerbations of COPD: Clinical practice guideline, part 1. Chest, 119:1185-9.
44. Soriano JB, Davis KJ, Coleman B, et al. 2003. The proportional Venn diagram of obstructive lung disease: two approximations from the United States and the United Kingdom. Chest, 124:474-81.
45. Spencer S, Jones PW; GLOBE Study Group. 2003. Time course of recovery of health status following an infective exacerbation of chronic bronchitis. Thorax, 58:589-93.
46. Swanson RN, Lainez-Ventosilla A, De Salvo MC, et al. 2005. Once-daily azithromycin for 3 days compared with clarithromycin for 10 days for acute exacerbation of chronic bronchitis: a multicenter, double-blind, randomized study. Treat Respir Med, 4:31-9.
47. Whitlock W. 1995. Ulticenter comparison of azithromycin and amoxicillin/ clavulanate in the treatment of patients with acute exacerbations of chronic obstructive pulmonary disease. Curr Ther Res, 56:985-95.
48. Wolter J, Seeney S, Bell S, et al. 2002. Effect of long term treatment with azithromycin on disease parameters in cystic fibrosis: a randomised trial. Thorax, 57:212-6.
49. Zachariah J. 1996. A randomized, comparative study to evaluate the efficacy and tolerability of a 3-day course of azithromycin versus a 10-day course of co-amoxiclav as treatment of adult patients with lower respiratory tract infections. J Antimicrob Chemother, 37(Suppl C):103-13.
50. Zeros M, Breen JD, Jorgensen DM, et al. 2005. Novel, single-dose microsphere formulation of azithromycin versus levofloxacin for the treatment of acute exacerbations of chronic bronchitis. Infect Dis Clin Pract, 13:1-7.
51. Zervos M, Martinez FJ, Amsden GW, et al. 2007. Efficacy and safety of 3-day azithromycin versus 5-day moxifloxacin for the treatment of acute bacterial exacerbations of chronic bronchitis. Int J Antimicrob Agents, 29:56-61.
52. Zmax package insert. Accessed December 2006. URL:www.Pfizer.com.